The convergence of HRD-associated genomic instability, PARP-induced cGAS-STING activation, and PD-L1 upregulation provides a strong rationale for combining PARP inhibitors with PD-1/PD-L1 blockade in gynecological cancers [21,22,25-32]. The gene discussed is PDCD1; the disease is female reproductive organ cancer.